Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy
Authors:
Open Access
- 1 February 2007
- journal article
- review article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 85 (2) , 333-345
Abstract
In HIV-infected persons, low serum concentrations of vitamins and minerals, termed micronutrients, are associated with an increased risk of HIV disease progression and mortality. Micronutrient supplements can delay HIV disease progression and reduce mortality in HIV-positive persons not receiving highly active antiretroviral therapy (HAART). With the transition to more universal access to HAART, a better understanding of micronutrient deficiencies and the role of micronutrient supplements in HIV-positive persons receiving HAART has become a priority. The provision of simple, inexpensive micronutrient supplements as an adjunct to HAART may have several cellular and clinical benefits, such as a reduction in mitochondrial toxicity and oxidative stress and an improvement in immune reconstitution. We reviewed observational and trial evidence on micronutrients in HIV-positive persons receiving HAART to summarize the current literature and suggest future research priorities. A small number of observational studies have suggested that some, but not all, micronutrients may become replete after HAART initiation, and few intervention studies have found that certain micronutrients may be a beneficial adjunct to HAART. However, most of these studies had some major limitations, including a small sample size, a short duration of follow-up, a lack of adjustment for inflammatory markers, and an inadequate assessment of HIV-related outcomes. Therefore, few data are available to determine whether HAART ameliorates micronutrient deficiencies or to recommend or refute the benefit of providing micronutrient supplements to HIV-positive persons receiving HAART. Because micronutrient supplementation may cause harm, randomized placebo-controlled trials are needed. Future research should determine whether HAART initiation restores micronutrient concentrations, independent of inflammatory markers, and whether micronutrient supplements affect HIV-related outcomes in HIV-positive persons receiving HAART.Keywords
This publication has 143 references indexed in Scilit:
- Emerging Role of Riboflavin in the Treatment of Nucleoside Analogue-Induced Type B Lactic AcidosisAIDS Patient Care and STDs, 2001
- Iron supplementation during human immunodeficiency virus infection: a double-edged sword?Medical Hypotheses, 2001
- Highly Active Antiretroviral Therapy Associated with Improved Anemia Among HIV-Infected WomenAIDS Patient Care and STDs, 2001
- Restored Antioxidant Capacity Parallels the Immunologic and Virologic Improvement in Children with Perinatal Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral TherapyClinical Immunology, 2001
- Weight Loss and Wasting Remain Common Complications in Individuals Infected with Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2000
- Acute‐phase reactants and plasma trace element concentrations in non‐small cell lung cancer patients and controlsNutrition and Cancer, 1997
- Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virusAmerican Journal of Hematology, 1995
- Malabsorption and deficiency of vitamin B12 in HIV-infected patients with chronic diarrheaDigestive Diseases and Sciences, 1994
- Inhibition of NF-κB Activation by Vitamin E DerivativesBiochemical and Biophysical Research Communications, 1993
- Vitamin B12 injections in patients treated with zidovudineAIDS, 1990